RxDoctor Payments Data

Jayesh Gosai, MD

Internal Medicine · Rices Landing, PANPI 1841253937

Payments from drug & device makers

$316in general payments, 2019–2025

Across 14 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$85
  • Lilly USA, LLC$83
  • Pfizer$44
  • Novo Nordisk$37
  • Exact Sciences$23
  • E.r. Squibb & Sons, L.L.C.$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$23173%
  • Education$8527%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$316 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$192,840
Medicare patients
186
Services billed
6,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide138$168,397
OzempicSemaglutide147$147,906
EliquisApixaban70$72,382
JardianceEmpagliflozin21$25,473
XareltoRivaroxaban21$22,188
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$16,896
Repatha SureclickEvolocumab18$14,589
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$11,794
Praluent PenAlirocumab12$9,743
Enoxaparin Sodium20$4,906
Tamsulosin Hcl163$3,362
Levothyroxine Sodium235$3,148
Losartan Potassium253$2,901
Nebivolol Hcl65$2,479
Albuterol Sulfate HfaAlbuterol Sulfate68$2,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$83$168,397138 claims
Novo NordiskOzempic$37$147,906147 claims
PfizerEliquis$44$72,38270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Rices Landing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →